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Psychotropic drug use in a group of Dutch nursing home patients with 
dementia: many users, long-term use, but low doses
• R .T .C .M . Koopmans, J.M . van Rossum, H .J.M . van den Hoogen, Y .A . Hekster, 
M .A .J.H , W illekens-Bogaers and C, van Weel
Introduction
Dementia is a progressive disease. The main symp­
toms are memory dysfunctions, disturbances of 
judgement, and, at a later stage, aphasia, agnosia, 
and apraxia [1 2]. In addition, 'non-cognitive' or 
behavioural symptoms are often observed, such as 
personality disorders, delusions, or depression [2]. 
Behavioural disturbances can be a major source of 
distress and a burden for patients and/or their care­
givers. Sometimes patients have to be institutional­
ized in a nursing home because of serious behav­
ioural disturbances.
Dutch psychogeriatric nursing homes offer an en­
vironment that is tolerant of behavioural problems. A 
multidisciplinary team including a specially trained 
'Dutch nursing home doctor' generates an individual 
management plan to approach this problematic 
behaviour. Psychotropic drugs are only prescribed if 
these approaches are no longer effective. Our investi­
gation has shown behavioural disturbances in 70% 
of a group of nursing home patients with dementia. 
Agitation, negativism, depression, anxiety, psychosis, 
and aggression were most frequently observed. If 
there is a need for pharmacotherapeutic interven­
tion, neuroleptics, benzodiazepines, and antidepres­
sants have an important role in the alleviation of 
these symptoms [3].
There are few data available about the prescription 
of psychotropic drugs in Dutch nursing homes. Data 
indicate that 28-41% of the patients are treated with 
psychotropics [4], of which 27-31% are treated with 
neuroleptics [5-7], 8-22% with benzodiazepines [6- 
8], and 2-7% with antidepressants [7]. Data from 
international literature indicate that 26-87% of 
patients suffering from dementia are treated with at 
least one psychotropic drug [9-13]. Neuroleptics are 
prescribed in 12-47% of patients [6 7 10-15], benzo­
diazepines in 9-24% of patients [10-13], and anti­
depressants in 7-11 % of patients [10-13].
Elderly people, and in particular those who suffer 
from dementia, are very susceptible to the side- 
effects of psychotropics and this warrants reservation 
in prescription. A high percentage of patients are 
reported to experience side-effects of neuroleptics 
such as sedation, extrapyramidal symptoms, and 
postural hypotension [61216-19]
In 1984 doctors of "Joachim en Anna" nursing 
home developed a protocol for the rational pre­
scription of neuroleptics [20]. On the basis of recep- 
tor-antagonism profiles, five relatively 'safe' neuro­
leptics were chosen [20], Haloperidol was proposed 
as the drug of first choice for the treatment of 
psychotic behaviour (delusions and hallucinations) 
with agitation. Bromperidol was prescribed for the 
treatment of psychosis without agitation, and pipam- 
perone for the treatment of aggression, negativism, 
and disturbances of diurnal rhythm. Zuclopenthixol 
was prescribed for the treatment of so-called 
'aspecific' behavioural disturbances (mostly combi-
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Abstract
The aim of this study was to describe the use of 
psychotropic drugs in a psychogeriatric nursing home, 
"Joachim en Anna", in Nijmegen, the Netherlands. To this 
end the medical records of 890 nursing home patients with 
dementia, admitted between 1980 and 1989, were analysed 
retrospectively. Each time pattern of psychotropic drug use 
was registered. Drugs were coded by means of the 
Anatomical Therapeutic Chemical classification system. The 
daily dose was expressed as the ratio of the mean prescribed 
daily dose and the defined daily dose. Side-effects and 
changes in prescription patterns throughout the years 
patients were admitted were analysed. A total of 3,090 time 
patterns of exposure to psychotropics were registered. 
Neuroleptics, benzodiazepines, and antidepressants 
accounted for 58, 32, and 9% of the time patterns, 
respectively. For almost every drug prescription the 
prescribed daily dose was lower than the defined daily dose. 
More than 75% of these nursing home patients had at least 
one prescription for a psychotropic drug during 
institutionalization. One or more side-effects were observed 
in 50% of the patients who used a neuroleptic. The total 
number of patients receiving psychotropics did not change 
throughout the study. Psychotropics were prescribed for 
long-term use, but in a low dose. Side-effects were 
frequently observed while the correct individual dose was 
being determined.
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nations of psychosis, aggression, anxiety, and nega­
tivism) and dehydrobenzperidol for interventions of 
short duration, for example, to prepare patients for 
invasive treatments like catheterization [20]. In 1990 
this schedule was evaluated, with special attention 
being paid to efficacy and side-effects [6]. The cur­
rent study addressed, in detail, the prescription of 
neuroleptics, benzodiazepines, and antidepressants, 
and changes in prescription patterns during the last 
12 years. The aim of the study was to assess the use 
of psychotropic drugs in this nursing home with 
regard to the type of drug, the number of patients 
treated, the duration of use and dosage, changes in 
these aspects of psychotropic drug use between 
1980 and 1992, and the prevalence of side-effects.
Methods
Patients
The study was a retrospective analysis of medical 
records. AH patients with dementia according to 
DSM-III-R criteria [1] who were admitted to the 
"Joachim en Anna" nursing home in Nijmegen, the 
Netherlands, between 1 January 1980 and 31 
December 1989 were included in the study. Follow- 
up data were collected until death or the end of the 
registration period in April 1992. Methods of data 
collection have been described previously [21 22].
"Joachim en Anna" is a nursing home with 
250 beds. Most patients suffer from dementia. All 
patients are initially admitted on the same ward. In 
the first 6 weeks of institutionalization a full medical 
and neuropsychological examination is carried out. 
Afterwards patients are referred to one of the long- 
stay wards, where patients with a similar stage of 
dementia live together.
Psychotropic drug use
Psychotropic drug use was continuously registered 
from the day of admission. Data were obtained from 
the medication list of the medical record. Each time 
pattern (time window or risk window) of drug ex­
posure, including one single dosage, was registered 
[23-25]. A time pattern of drug exposure was de­
fined as an uninterrupted period of usage of the 
same drug. A change of dose between times was not 
considered a new time pattern.
Drugs were classified by means of the Anatomical 
Therapeutic Chemical (ATC) classification system 
[26]. The ATC system uses five levels of classification. 
The first, second, and third levels refer to an ana­
tomical group with two therapeutic subgroups. The 
fourth level refers to the chemical/therapeutic sub­
group, and the fifth level refers to the active com­
ponent [26]. For example, the code N05AF05 stands 
for zuclopenthixol. In this study we used the fourth 
level. Drug dosages were expressed according to 
the defined daily dose (DDD) methodology rec­
ommended by the WHO Drug Utilization Research 
Group for pharmacoepidemiological research [27]. In 
addition (mean) actual prescribed doses were re­
corded (PDD) and the ratio PDD to DDD was calcu­
lated. A PDD/DDD ratio < 1 indicates that the drug is 
prescribed in a lower dosage than recommended; a 
ratio > 1 indicates that the prescribed dosage is 
higher than recommended. For example, the DDD 
for haloperidol is 8 mg per day. When a mean of 
2 mg per day is prescribed, the PDD/DDD ratio is
0.25. Furthermore whether a drug was withdrawn or 
continued at admission or whether the drug was 
administered during institutionalization was re­
corded.
Side-effects mentioned in the medical records were 
classified with the International Classification of 
Heaith Problems in Primary Care (ICHPPC)-2-defined 
[28]. The code 9952 (side-effect medical agent cor­
rectly administered in proper dosage) was supple­
mented with codes for medication group and type of 
side-effect [28],
To investigate changes in psychotropic prescrip­
tion time patterns throughout the time patients were 
admitted, it was studied whether the prescription of 
neuroleptics after 1984 was consistent with the pro­
tocol. Changes in the percentage of patients treated 
and in the duration of usage were investigated by 
dividing the study population into 10 cohorts (one 
cohort for each year). For a proper comparison, 
figures were corrected for the time that patients 
spent in the nursing home. Changes were studied by 
means of linear regression analysis [29].
Results
During the study period 890 patients with dementia 
were admitted to the nursing home, of whom 102 
survived until April 1992; 70% of the patients were 
women. The mean time spent in the nursing home 
was 2.2 years, with a range from 0 to 10.6 years.
A total of 3,294 time patterns of psychotropic drug 
exposure were registered. 204 drugs were with­
drawn on the day of admission. Therefore this study 
is based on the 3,090 remaining time patterns. A 
mean of 4.5 time patterns per user was registered 
(range 1-35 time patterns per user). In Table 1, the 
number of time patterns, the mean duration of drug 
exposure, the mean daily dose, and the PDD/DDD 
ratio are listed for the drugs that were actually ad­
ministered during institutionalization (3,090 time 
patterns). Neuroleptics, benzodiazepines, and anti­
depressants accounted for 58, 32, and 9% of the 
time patterns, respectively. Because time patterns 
vary in duration, these percentages do not give valid 
information about the contribution of neuroleptics, 
benzodiazepines, and antidepressant to the prescri­
bing pattern.
The nine most frequently prescribed drugs were 
zuclopenthixol, haloperidol, pipamperone, oxaze-
pam, nitrazepam, lormetazepam, trazodone, amitrip­
tyline, and doxepin (Table 1). These covered about 
70% of ail time patterns prescribed. For almost all 
drugs the mean PDD was much lower than the DDD. 
For neuroleptics 25% of the DDD was prescribed, 
while for benzodiazepines and antidepressants this 
was 50% and 33%, respectively (Table 1).
During institutionalization more than 75% of the 
study population received one or more psychotropics 
(Table 2). Most patients were treated with a neuro­
leptic, 50% of the patients received a benzodiaze­
pine, and 20% received an antidepressant. Also com­
binations of medications were frequently prescribed. 
A neuroleptic in combination with a benzodiazepine 
was administered in 252 patients. 142 patients re­
ceived two neuroleptics at the same time (Table 2).
In general, psychotropics were prescribed for a 
long period. The median duration of the time pat­
terns was 245 days. It has to be noted that a time 
pattern was ended when a patient died or when the 
registration period ended. More than 50% of the 
users of psychotropic drugs had a time pattern of 
drug exposure for 50 to 100% of their time spent in 
the nursina home.
More side-effects were associated with the use of 
neuroleptics than with the use of benzodiazepines or 
antidepressants (Table 3). One or more side-effects 
were observed in 50% of the patients who used 
neuroleptics. Excessive sedation was the most fre­
quently reported problem in the medical records.
After 1984, a neuroleptic that was not included in 
the schedule was prescribed only thirteen times. 
Drugs such as levomepromazine, propericiazine, 
thioridazine, alimemazine, promazine, perazine, and 
chlorpromazine almost totally disappeared from the 
prescription list.
Neither the total percentage of psychotropic drug 
used (expressed as neuroleptics, benzodiazepines, 
and antidepressants) nor the duration of usage 
changed throughout the time patients were ad­
mitted. Most figures showed fluctuations without a 
statistically significant rising or falling trend.
Discussion
At any time during institutionalization in this nursing 
home, more than 75% of the patients with dementia 
were prescribed a psychotropic drug. Neuroleptics
Table 1 Number of drug-time patterns (n = 3090), mean duration of exposure, mean daily dose and
prescribed daily dose-defined dally dose (PDD/DDD) ratio of the prescribed psychotropics during 
institutionalization
'  * * " b
Generic name Number of Mean duration Mean dose Mean PDD/DDD
time patterns (days) (mg) ratio
Neuroleptics 1803 131 (0-3203) 0.25
• Zuclopenthixol 600 135 5.4 0.18
• Haloperidol 330 123 1.5 0.19
• Pipamperone 291 149 33.6 0.17
• Alimemazine 179 146 24.0 0.80
• Bromperidol 124 153 ■ 1.4 0.14
• Dehydrobenzperidol 105 85
9 ’
4.2 0.28
• Propericiazine 62 94 13.4 0.27
• Sordinol 44 119 12.7 0.13
• Thioridazine 21 112 57.6 0.19
• Perazine 17 42 53.6 0.54
• Promazine 12 101 52.2 0.17
é  i
Benzodiazepines 989 120(0-2048) 0.55 *
• Oxazepam 497 130
. i ”' -  ,
15.8 0.32
• Temazepam 210 101 11.8 0.59
• Lormetazepam 137 1 36 1.0 1.01
• Nitrazepam
k * < ' »
90 129 4.0 0.81
•Diazepam 50 46 10.9 1.08
» s '  •  • 
Antidepressants
s
« '  S *
289 171 (1-1563)
*
0.36
* s t  »
• Trazodone
« t t  
r  '  >
112
*  %
176 109.9 0.37
•Amitriptyline 56 160 33.5 0.45
• Doxepin .  51 ■ . 190
* ^  « 4 « ,
25.8 0.26
• Mianserin 47 '
'  '  V * *  ,
163 19.7 033
• Mapritiíine ¡ 10 -■ 545 51.4 0.51
Not listed are levomepromazine, sulpiride, chlorpromazine, chlorprothixene, flurazepam, chlordiazepoxide, 
flunitrazepam, lorazepam, nomifensine, clomipramine, imipramine, lithium carbonate, and promethazine. 
These medications: were each prescribed less than 10 times.
Table 2 Number of patients treated with neuroleptics, benzodiazepines, and antidepressants, parallel
prescriptions* and median duration of exposure expressed in days
Patients (n -  890) Median duration of
exposure (days)
n % «
At least 1 time pattern for a psychotropic 683 77 245
At least 1 time pattern for a neuroleptic 554 62 204
At least 1 time pattern for a benzodiazepine 456 51 107
At least 1 time pattern for an antidepressant 199 22 83
Paraliel prescription
2 neuroleptics 142 16 57
2 benzodiazepines 45 5 33
2 antidepressants 6 1 55
1 neuroleptic + 1 benzodiazepine 252 28 84
1 benzodiazepine + 1 antidepressant 74 8 36
1 neuroleptic + 1 antidepressant 91 10 56
1 neuroleptic + 1 benzodiazepine + 1 antidepressant 3 4 27
* Parallel prescription means that one or more drugs were prescribed at one time.
were most frequently prescribed, followed by benzo­
diazepines and antidepressants. Psychotropic drugs 
usually were prescribed for long-term use but in a 
relatively low dose. All these figures reflect the pre­
scribing policy of one team of Dutch nursing home 
doctors. Therefore the results cannot be generalized 
to all Dutch nursing home patients.
The results are difficult to compare with inter­
national data. In this study, data were registered con­
tinuously, while most other studies have a cross- 
sectional design. Most studies do not report dosage 
and duration of use. The fact that the PDD was much 
lower than the internationally agreed DDD can be 
explained by the advanced age of these nursing 
home patients. Changes in pharmacodynamics and 
pharmacokinetics in elderly people increase the risk 
of cumulation and therefore the dosage has to be 
adjusted [30]. In addition, elderly people, and es­
pecially those with an organic brain syndrome, have
a higher end-organ sensitivity for psychotropic drugs 
[30], These and other mechanisms account for most 
of the observed side-effects. In particular, neuro­
leptics caused side-effects which led to adjustment of 
the dose or even withdrawal of the drug. It has to be 
mentioned that patients were not systematically 
checked for signs of sedation, extrapyramida! signs, 
or other symptoms. Therefore the figures reported 
here are most likely an underestimation of the real 
frequency and only express the recognized side- 
effects.
Neuroleptics can be effective in very low doses [6 
17], Willekens-Bogaers and coworkers found in their 
evaluation study that in 69% of their patients, who 
were also included in our investigation, psychosis, 
and/or behavioural disturbances could be reduced to 
an acceptable level [6]. This agrees with the finding 
of Schneider and coworkers. They concluded in their 
meta-analysis that neuroleptics were of benefit to
Table 3 Percentage of patients showing side-effects of antidepressants (n = 556), neuroleptics (n = 457),
and benzodiazepines (n -  199)
Side-effect* .Antidepressants Neuroleptics Benzodiazepines
Sedation 41 11 8
Gait disorder 5 2 2
Falling 2 1 1 
Extra pyramidal signs /  9 -
Cardiovascular problem 3 -  2
Paradox reactions 3 1 1
* More than one side-effect could be observed per patient
Total 50 15 14
59% of patients with dementia; however, 41% of 
patients also improved on placebo therapy [31].
There are few studies about the efficacy of benzo­
diazepines or antidepressants in patients with 
dementia [32]. It is clear that doctors and nursing 
staff play an important role in judging the effects of 
psychotropics. In a nursing home, the tolerance of 
disturbing behaviour is high. Therefore better out­
comes are probably achieved than with treatment 
given at home. Psychotropic drugs have to be 
administered in a dynamic way. In the search for the 
correct dose, the motto is "start low and go slow" 
[20], The correct dose has to be determined on the 
basis of efficacy and side-effects (titration method). 
Therefore psychotropic drug prescription has to be 
accurately monitored by the (nursing home) doctor. 
Former investigations showed that psychotropic drug 
use can be reduced when a patient is admitted to a 
nursing home [33]. During institutionalization, how­
ever, drug use increases but after 2 years a steady 
decrease has been noted [34].
The high number of time patterns per patient and 
the wide range in these patterns reflect a continuous 
search for the right and most effective drug. The 
frequent changes of type of drugs can be explained 
by our clinical experience. Patients alternately show 
agitation, negativism, and anxiety, and so the target 
symptoms change with tíme.
The prescription of combinations of drugs may 
indicate the complexity of symptomatic treatment of 
behavioural problems in these patients. Prescription 
of a neuroleptic in combination with a benzodiaze­
pine can be a rational choice for treatment of agi­
tation in the daytime and sleep disturbance during 
the night. But prescription of two neuroleptics at one 
time indicates difficulties in managing behaviour. 
When there is a need for dopamine as well as seroto­
nin receptor antagonism, treatment with two neuro­
leptics can be a rational therapy. Recent studies show 
that extra pyramidal side-effects can be reduced by 
using these combinations of drugs [35 36]. In clinical 
practice, however, treatment outcomes are not 
always satisfying, so sometimes trial-and-error 
methods have to be used.
This investigation did not find any statistically sig­
nificant changes in drug prescription patterns 
throughout the years patients were admitted. This 
finding is in contrast with our impression that more 
patients with serious behavioural disturbances have 
been admitted in the last years. Patients with 
Alzheimer's disease without behavioural problems 
can stay at home either with intensive home care or 
with day care if they live in residential homes. How­
ever, an increase in behavioural disturbances does 
not necessarily have to result in the prescription of 
more psychotropic drugs.
C onclusion
Despite a tolerant setting and multidisciplinary thera­
peutic approach, most of the patients in this psycho­
geriatric nursing home manifested behaviour for 
which psychotropics were prescribed. Psychotropics 
were prescribed for a long period but in a relatively 
low dosage. Side-effects were frequently observed 
during the search for the correct dosage.
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